GastroenterologyOphthalmologyRheumatologyImmunologyOncologyCardiovascularOsteoporosisNeurologyAutomotiveBiotechnologyHealth Care
Description
Celltrion, Inc., a biopharmaceutical company, focusing on developing, manufacturing, and commercializing proprietary biosimilars and innovative monoclonal antibodies. With a strong commitment to enhancing patient care through accessible medical treat…
Analysis
Middle-of-the-road
Celltrion, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.
The price is fair. You pay 24.4× its owner earnings: the cash an owner could take out each year, which is in the historically fair zone. At today's price, the market is assuming roughly 9% yearly growth; analysts expect 40%. The price, in other words, assumes less than the experts do.
The trajectory is solid and the balance sheet is adequate. The company scores 12/20 on our value-creation score: creating some value.
What to watch: Some accounting patterns deserve a closer look. A large part of the company's book value is the price paid for past acquisitions. Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Mar 202696
100
2026
All-time high
100
Jun 2026
All-time low
96
Mar 2026
Average rank
98
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
16
—
—
—
Price/Earnings
31
—
—
—
Price/Book
45
—
—
—
Dividend Yield
65
—
—
—
Value (overall)
46
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.